Department of Radiation Oncology, European Institute of Oncology IRCCS, 20141, Milan, Italy.
Unit of Medical Physics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Radiol Med. 2023 Dec;128(12):1553-1570. doi: 10.1007/s11547-023-01706-6. Epub 2023 Aug 31.
The strategy to anticipate radiotherapy (RT) before surgery, for breast cancer (BC) treatment, has recently generated a renewed interest. Historically, preoperative RT has remained confined either to highly selected patients, in the context of personalized therapy, or to clinical research protocols. Nevertheless, in the recent years, thanks to technological advances and increased tumor biology understanding, RT has undergone great changes that have also impacted the preoperative settings, embracing the modern approach to breast cancer. In particular, the reappraisal of preoperative RT can be viewed within the broader view of personalized and tailored medicine. In fact, preoperative accelerated partial breast irradiation (APBI) allows a more precise target delineation, with less variability in contouring among radiation oncologists, and a smaller treatment volume, possibly leading to lower toxicity and to dose escalation programs. The aim of the present review, which represents a benchmark study for the AIRC IG-23118, is to report available data on different technical aspects of preoperative RT including dosimetric studies, patient's selection and set-up, constraints, target delineation and clinical results. These data, along with the ones that will become available from ongoing studies, may inform the design of the future trials and representing a step toward a tailored APBI approach with the potential to challenge the current treatment paradigm in early-stage BC.Trial registration: The study is registered at clinicaltrials.gov (NCT04679454).
术前放疗(RT)策略在乳腺癌(BC)治疗中最近重新引起了关注。从历史上看,术前 RT 一直局限于高度选择的患者,或者在个性化治疗的背景下,或者在临床研究方案中。然而,近年来,由于技术进步和肿瘤生物学理解的提高,RT 发生了重大变化,这也影响了术前环境,采用了现代乳腺癌治疗方法。具体而言,术前 RT 的重新评估可以在个性化和量身定制医学的更广泛视角下进行观察。事实上,术前加速部分乳腺照射(APBI)允许更精确的靶区勾画,在轮廓勾画方面,放射肿瘤学家之间的差异较小,治疗体积更小,可能导致毒性降低和剂量升级方案。本综述的目的是报告术前 RT 的不同技术方面的现有数据,包括剂量学研究、患者选择和设置、限制因素、靶区勾画和临床结果,这是 AIRC IG-23118 的基准研究。这些数据,以及即将从正在进行的研究中获得的数据,可能为未来试验的设计提供信息,并代表朝着量身定制的 APBI 方法迈出的一步,有可能挑战早期 BC 目前的治疗模式。
该研究在 clinicaltrials.gov 注册(NCT04679454)。